Document:

Loan and Security Agreement

 Exhibit 10.1 
 LOAN AND SECURITY AGREEMENT 
 THIS LOAN AND SECURITY AGREEMENT is made and dated
as of February 28, 2011 and is entered into by and between AEGERION PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), with its chief executive office and principal place of business located at 101 Main Street, Suite 1850,
Cambridge, MA 02142, and HERCULES TECHNOLOGY II, L.P., a Delaware limited partnership, and HERCULES TECHNOLOGY III, L.P., a Delaware limited partnership (collectively, “Lender”), each with its principal place of business located at 400
Hamilton Avenue, Palo Alto, CA 94301. 
 RECITALS 
 WHEREAS, Borrower has requested Lender to make available to Borrower a loan in an aggregate principal amount of up to $25,000,000 (the “Loan”); and 

WHEREAS, Lender is willing to make the Loan on the terms and conditions set forth in this Agreement. 

AGREEMENT 
 NOW,
THEREFORE, Borrower and Lender agree as follows: 
 SECTION 1. DEFINITIONS AND RULES OF CONSTRUCTION 

1.1. Unless otherwise defined herein, the following capitalized terms shall have the following meanings: 

“Account Control Agreement(s)” means any agreement entered into by and among Lender, Borrower and a third party Bank or other
institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or Investment Property and which is intended to perfect Lender’s security interest in any of the Collateral. 

“Advance” means any funds advanced under this Agreement. 

“Advance Date” means the funding date of any Advance. 
 “Advance Request” means a request for an Advance submitted by Borrower to Lender in substantially the form of Exhibit A. 

“Agreement” means this Loan and Security Agreement, as the same may from time to time be amended, modified, supplemented or
restated from time to time in accordance with the terms hereof. 
 “Amortizing Principal Balance” has the meaning
given to it in Section 2.2. 
 “Borrower Products” means all products, software, service offerings, technical
data or technology currently being designed, manufactured or sold by Borrower or which Borrower intends to sell, license, or distribute in the future including any products or service offerings under development, collectively, together with all
products, software, service offerings, technical data or technology that have been sold, licensed or distributed by Borrower since its incorporation. 
 “Cash” means all cash and liquid funds. 
 “Closing Date” means
the date of this Agreement. 
 “Collateral” means the property described in Section 3. 

“Collateral Agent” means Hercules Technology II, L.P. 
 “Contingent Obligation” means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any indebtedness, lease, dividend,
letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, co-made 

  
 1. 

 
or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of
credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar
agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices, in each case payable on or prior to the Maturity Date; provided, however, that the term
“Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the
primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such
amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement. 

“Copyrights” means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any
State thereof, or of any other country. 
 “Copyright License” means any written agreement granting any right to use
any Copyright or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 
 “Deposit Accounts” means any “deposit accounts,” as such term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Event of Default” has the meaning given to it in Section 9. 

“Facility Fee” means $62,500, which fee is due to Lender on the Closing Date. 

“Financial Statements” has the meaning given to it in Section 7.1. 

“GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time.

 “Indebtedness” means indebtedness of any kind, including (a) all indebtedness for borrowed money or the
deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business due within ninety (90) days), including reimbursement and other obligations with respect to surety bonds and letters of
credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations. 
 “Intellectual Property” means all of Borrower’s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; Borrower’s applications therefor and reissues, extensions, or
renewals thereof; and Borrower’s goodwill associated with any of the foregoing, together with Borrower’s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith. 

“Interest Rate” means for any day, the greater of (i) 10.4% per annum or (ii) 10.4% plus (a) the Prime Rate
as reported in The Wall Street Journal minus (b) 4.75%. 
 “Investment” means any beneficial ownership of
or in any Person (including stock , partnership or limited liability company interests), or any loan, advance or capital contribution to any Person. 
 “Joinder Agreements” means for each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto as Exhibit G. 

“Lender” has the meaning given to it in the preamble to this Agreement. 

  
 2. 

 “License” means any Copyright License, Patent License, Trademark License or other
license of rights or interests. 
 “Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for
security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, any lease in the
nature of a security interest, and the filing of any financing statement (other than a precautionary financing statement with respect to a lease that is not in the nature of a security interest) under the UCC or comparable law of any jurisdiction.

 “Loan” has the meaning given to it in the recitals to this Agreement. 

“Loan Documents” means this Agreement, the Notes, Account Control Agreements, Joinder Agreements, all UCC Financing Statements,
and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated. 

“Material Adverse Effect” means a material adverse effect upon: (i) the business, operations, or financial condition of
Borrower and its subsidiaries, taken as a whole other than an effect in and of itself reasonably attributable to (a) the failure of any nonclinical or clinical trial to demonstrate the desired safety or efficacy of any biologic or drug or
(b) the denial, delay or limitation of approval of, or taking of any other regulatory action by, the United States Food and Drug Administration or any other governmental entity with respect to any biologic or drug; or (ii) the ability of
Borrower to perform the Secured Obligations when due in accordance with the terms of the Loan Documents, or the ability of Lender to enforce its rights or remedies with respect to the Secured Obligations; or (iii) the Collateral or
Lender’s Liens on the Collateral or the priority of such Liens, in each case, in the aggregate. 
 “Maturity
Date” means September 1, 2014. 
 “Maximum Loan Amount” means $25,000,000. 

“Maximum Rate” shall have the meaning assigned to such term in Section 2.5. 

“Merger” means an event or series of events by which any “person” or “group” (as such terms are used in
Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act, except that a person or group shall be deemed to have “beneficial ownership” of all
securities that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time (such right, an “option right”)), directly or indirectly, of 50% or more of the equity
securities of Borrower entitled to vote for members of the Board of Directors of Borrower on a fully-diluted basis (and taking into account all such securities that such “person” or “group” has the right to acquire pursuant to
any option right). 
 “Notes” means the Promissory Notes in substantially the form of Exhibit B-1 and
Exhibit B-2. 
 “Patent License” means any written agreement granting any right with respect to any invention
on which a Patent is in existence or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest. 
 “Patents” means all letters patent of, or rights corresponding thereto, in the United States or in any other country, all registrations and recordings thereof, and all applications for letters
patent of, or rights corresponding thereto, in the United States or any other country. 
 “Permitted Indebtedness”
means: (a) Indebtedness of Borrower in favor of Lender arising under this Agreement or any other Loan Document; (b) Indebtedness existing on the Closing Date and disclosed in Schedule 1A; (c) Indebtedness not to exceed
$1,500,000 in the aggregate in any fiscal year of Borrower secured by a lien described in clause (vi) of the defined term “Permitted Liens,” provided such 

  
 3. 

 
Indebtedness does not exceed the lesser of the cost or fair market value of the equipment (including any related software) financed with such Indebtedness; (d) Indebtedness to trade
creditors or contractual counterparties incurred in the ordinary course of business, including Indebtedness incurred in the ordinary course of business with corporate credit cards; (e) Indebtedness that also constitutes a Permitted Investment;
(f) Subordinated Indebtedness; (g) reimbursement or other obligations in connection with surety bonds or letters of credit issued on behalf of Borrower or a Subsidiary for the benefit of customers or suppliers entered into in the ordinary
course of business not to exceed $250,000; and (h) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose materially more burdensome
terms upon Borrower or its Subsidiary, as the case may be. 
 “Permitted Investment” means: (a) Investments
existing on the Closing Date disclosed in Schedule 1B or made in accordance with the Investment Policy approved by Borrower’s Board of Directors, a copy of which has been delivered to Lender; (b) (i) marketable direct
obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one year from the date of acquisition thereof, (ii) commercial paper maturing no more than one year from the
date of creation thereof and currently having rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s Investors Service, (iii) certificates of deposit issued by any bank with assets of at least
$500,000,000 maturing no more than one year from the date of investment therein, and (iv) money market accounts; (c) repurchases of stock from former employees, directors, or consultants of Borrower under the terms of applicable repurchase
agreements at the original issuance price of such securities (i) in an aggregate amount not to exceed $100,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist after giving effect to the
repurchases, or (ii) in any amount where the consideration for the repurchase is the cancellation of indebtedness owed by such former employees, directors, or consultants, to Borrower regardless of whether an Event of Default exists;
(d) Investments accepted in connection with Permitted Transfers; (e) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent
obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; (f) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and
suppliers who are not affiliates, in the ordinary course of business, provided that this subparagraph (f) shall not apply to Investments of Borrower in any Subsidiary; (g) additional Investments that do not exceed $250,000 in the
aggregate; (h) Investments in newly-formed Subsidiaries organized in the United States, provided that such Subsidiaries enter into a Joinder Agreement promptly after their formation by Borrower and execute such other documents as shall be
reasonably requested by Lender; and (i) Joint ventures or strategic alliances in the ordinary course of Borrower’s business consisting of the nonexclusive licensing of technology, the development of technology or the providing of technical
support, provided that any cash Investments by Borrower do not exceed $250,000 in the aggregate in any fiscal year. 

“Permitted Liens” means any and all of the following: (i) Liens existing on the Closing Date disclosed in Schedule
1C; (ii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings; provided, that Borrower maintains adequate reserves therefor in
accordance with GAAP; (iii) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of Borrower’s business and imposed without action of
such parties; provided, that the payment thereof is not yet required; (iv) Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder; (v) the following deposits, to
the extent made in the ordinary course of business: deposits under worker’s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment
of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than liens arising under ERISA
or environmental liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; (vi) purchase money liens and 

  
 4. 

 
liens in connection with capital leases on Equipment (including any related software) securing Indebtedness permitted in clause (c) of “Permitted Indebtedness”; (vii) Liens
incurred in connection with Subordinated Indebtedness; (viii) leasehold interests in leases or subleases and licenses granted in the ordinary course of business and not interfering in any material respect with the business of the licensor;
(ix) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; (x) Liens on insurance proceeds securing the payment of
financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); (xi) statutory and common law rights of set-off
and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; (xii) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or
arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property; (xiii) Liens on cash or cash equivalents securing obligations permitted under clause (g) of the
definition of Permitted Indebtedness; and (xiv) Liens incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in clauses (i) through (vii) above; provided,
that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon)
does not increase. 
 “Permitted Transfers” means (i) sales of Inventory in the normal course of business,
(ii) licenses and similar arrangements for the use of property in the ordinary course of business, (iii) dispositions of worn-out, obsolete or surplus Equipment, and (iv) other Transfers of assets having a fair market value of not
more than $250,000 in the aggregate in any fiscal year. 
 “Person” means any individual, sole proprietorship,
partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government. 
 “Prepayment Fee” means for each Advance, an amount equal to (i) for a prepayment made on or before the first anniversary of the Closing Date, 2.0% of the principal amount of the Advance
prepaid, (ii) for a prepayment made after the first anniversary, but on or before the second anniversary of the Closing Date, 1.0% of the principal amount of the Advance prepaid, and (iii) for a prepayment made after the second anniversary
of the Closing Date, but before the Maturity Date, 0.5% of the principal amount of the Advance prepaid. 

“Receivables” means (i) all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations,
letters of credit, proceeds of any letter of credit, and Letter of Credit Rights, and (ii) all customer lists, software, and business records related thereto. 
 “SBA” shall have the meaning assigned to such term in Section 7.14. 

“SBIC” shall have the meaning assigned to such term in Section 7.14. 

“SBIC Act” shall have the meaning assigned to such term in Section 7.14. 

“Secured Obligations” means Borrower’s obligation to repay to Lender the Loan and all Advances (whether or not evidenced
by any Note), together with all principal, interest, fees, costs, professional fees and expenses, or other liabilities or obligations for monetary amounts owed by Borrower to Lender however arising, including the indemnity and insurance obligations
in Section 6 and including such amounts as may accrue or be incurred before or after default or workout or the commencement of any liquidation, dissolution, bankruptcy, receivership or reorganization by or against Borrower, whether due or to
become due, matured or unmatured, liquidated or unliquidated, contingent or non-contingent, and all covenants and duties of any kind or nature, present or future, in each case, arising under this Agreement, the Notes, or any of the other Loan
Documents, as the same may from time to time be amended, modified, supplemented or restated, whether or not such obligations are partially or fully secured by the value of Collateral. 

  
 5. 

 “Subordinated Indebtedness” means Indebtedness subordinated to the Secured
Obligations in amounts and on terms and conditions satisfactory to Lender in its sole discretion. 
 “Subsidiary”
means an entity, whether corporate, partnership, limited liability company, joint venture or otherwise, in which Borrower owns or controls 50% or more of the outstanding voting securities, including each entity listed on Schedule 1 hereto.

 “Trademark License” means any written agreement granting any right to use any Trademark or Trademark registration,
now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 

“Trademarks” means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including
registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof. 

“UCC” means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California;
provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Lender’s Lien on any Collateral is governed by the Uniform Commercial Code
as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes
of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. Unless otherwise defined herein or in the other Loan Documents, terms that are defined in the UCC and
used herein or in the other Loan Documents shall, unless the context indicates otherwise, have the meanings given to them in the UCC. 
 1.2. Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,” “subsection,” “Exhibit,” “Annex,” or
“Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents
shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied. 
 SECTION 2. THE LOAN 
 2.1. Advances. Subject to the terms and
conditions of this Agreement, Lender will make one (1) Advance to Borrower on or about the Closing Date in an amount equal to $10,000,000 or (ii) such greater amount as Borrower may request, up to the Maximum Loan Amount. If the initial
Advance is less than the Maximum Loan Amount, thereafter, at any time through July 29, 2011, Borrower may request additional Advances in the minimum amount of $7,500,000, up to the difference between the Maximum Loan Amount and the amount of
the initial Advance. If the sum of the first two Advances is less than the Maximum Loan Amount, thereafter, at any time through December 30, 2011, Borrower may request additional Advances in the minimum amount of $7,500,000, up to the
difference between the Maximum Loan Amount and the sum of the first two Advances. 
 2.2. Repayment. The principal
balance of each Advance shall bear interest thereon from the Advance Date, precomputed at the Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days in each month, through March 1,
2012. The aggregate principal balance outstanding on March 1, 2012 (the “Amortizing Principal Balance”), shall be amortized and shall be payable as follows: beginning April 1, 2012 and continuing on the first day of each month
through March 1, 2013, principal payments equal to 1/12 of 25% of the Amortizing Principal Balance; 

  
 6. 

 
beginning April 1, 2013 and continuing on the first day of each month through March 1, 2014, principal payments equal to 1/12 of 40% of the Amortizing Principal Balance; and beginning
April 1, 2014 and continuing on the first day of each month through the Maturity Date, principal payments equal to 1/6 of 35% of the Amortizing Principal Balance. Interest will be calculated based on the Interest Rate and will be payable with
each payment of the Amortizing Principal Balance. The entire principal balance and all accrued but unpaid interest hereunder, shall be due and payable on the Maturity Date. Borrower shall make all payments under this Agreement without setoff,
recoupment or deduction and regardless of any counterclaim or defense. 
 2.3. Advance Request. To obtain an Advance,
Borrower shall complete, sign and deliver an Advance Request and Note to Lender. Lender shall fund the Advance in the manner requested by the Advance Request provided that each of the conditions precedent to such Advance is satisfied as of the
requested Advance Date. 
 2.4. Prepayment. At its option, Borrower may prepay all or any portion (in a minimum amount of
$500,000) of the outstanding Advances by paying (i) the principal balance being prepaid, (ii) all accrued interest, (ii) the Prepayment Fee with respect thereto, and (iii) all other sums, if any, that shall have become due and
payable hereunder or under the Notes. 
 2.5. Maximum Interest. Notwithstanding any provision in this Agreement, the
Notes, or any other Loan Document, it is the parties’ intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto
(which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”). If a court of competent jurisdiction shall finally determine that Borrower
has actually paid to Lender an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall
be applied as follows: first, to the payment of principal outstanding on the Notes; second, after all principal is repaid, to the payment of Lender’s accrued interest, costs, expenses, professional fees and any other Secured
Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower. 

2.6. Default Interest. In the event any payment is not paid within five (5) business days of the scheduled Payment Date, an
amount equal to two percent (2%) of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest,
compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.2 plus five percent (5%) per annum. In the event any interest is not paid when due hereunder, delinquent interest
shall be added to principal and shall bear interest on interest, to the extent permitted by law, compounded at the rate set forth in Section 2.2 or Section 2.6, as applicable. 

2.7. Mandatory Prepayment. The outstanding amount of all principal and accrued interest and unpaid interest will become
immediately due and payable at Lender’s option (1) upon a Merger, or (2) the sale of substantially all assets of Borrower outside the ordinary course of business unless otherwise agreed to in writing by Lender. 

2.8. End of Term Charge. On the earliest to occur of (i) the Maturity Date, (ii) the date that Borrower prepays the
outstanding Secured Obligations, or (iii) the date that the Secured Obligations become due and payable, Borrower shall pay Lender a charge of $775,000. Notwithstanding the required payment date of such charge, it shall be deemed earned by
Lender as of the Closing Date. 
 SECTION 3. SECURITY INTEREST 
 3.1. As security for the prompt, complete and indefeasible payment when due (whether on the Payment Dates or otherwise) of all the Secured Obligations, Borrower grants to Lender a security interest in all
of Borrower’s right, title and interest in and to all of its personal property now owned or hereafter 

  
 7. 

 
acquired, including the following: (collectively, the “Collateral”): (a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles (other than Intellectual
Property); (e) Accounts; (f) Inventory; (g) Investment Property; (h) Deposit Accounts; (i) Cash; (j) Goods and other tangible and intangible personal property of Borrower whether now or hereafter owned or existing,
leased, consigned by or to, or acquired by, Borrower and wherever located; and (k) to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and
products of each of the foregoing, provided, however, that the Collateral does not include Intellectual Property, but shall include all Accounts and General Intangibles that consist of rights to payment and proceeds from the sale, licensing
or disposition of all or any part, or rights in, the Intellectual Property (the “Rights to Payment”). Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the
underlying Intellectual Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to
permit perfection of Lender’s security interest in the Rights to Payment. 
 SECTION 4. CONDITIONS PRECEDENT TO LOAN 

The obligations of Lender to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions: 

4.1. Initial Advance. On or prior to the Closing Date, Borrower shall have delivered to Lender the following: 

(a) executed originals of this Agreement, the Loan Documents, Account Control Agreement(s), a legal opinion of Borrower’s counsel,
Joinder Agreements, Guaranties, and all other documents and instruments reasonably required by Lender to effectuate the transactions contemplated hereby or to create and perfect the Liens of Lender with respect to all Collateral, in all cases in
form and substance reasonably acceptable to Lender; 
 (b) certified copy of resolutions of Borrower’s board of directors
evidencing approval of (i) the Loans and other transactions evidenced by the Loan Documents; 
 (c) certified copies of the
Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower; 
 (d) a certificate of good
standing for Borrower from its state of incorporation and similar certificates from all other jurisdictions in which it does business and where the failure to be qualified would have a Material Adverse Effect; 

(e) payment of the Facility Fee and reimbursement of Lender’s current expenses reimbursable pursuant to Section 11.11, which
amounts may at Borrower’s election be deducted from the initial Advance; and 
 (f) such other documents as Lender may
reasonably request. 
 4.2. All Advances. On each Advance Date: 

(a) Lender shall have received (i) an Advance Request for the relevant Advance as required by Section 2.3, duly executed by
Borrower’s Chief Executive Officer or Chief Accounting Officer, (ii) duly executed Notes evidencing such Advance, and (iii) any other documents Lender may reasonably request. 

(b) The representations and warranties set forth in this Section 4 and in Section 5 shall be true and correct in all material
respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date. 

  
 8. 

 (c) Borrower shall be in compliance in all material respects with the terms and provisions
set forth herein and in each other Loan Document on its part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing. 

(d) Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the
matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request. 
 4.3. No Default. As of the Closing Date and each Advance Date, (i) since the delivery of the most recent financial statements of Borrower delivered in accordance with Sections 7.1(a)-(c), no
fact or condition exists that would constitute an Event of Default and (ii) no event that has had or could reasonably be expected to have a Material Adverse Effect, has occurred and is continuing. 

SECTION 5. REPRESENTATIONS AND WARRANTIES OF BORROWER 
 Borrower represents and warrants that: 
 5.1. Corporate Status. Borrower is
a corporation duly organized, legally existing and in good standing under the laws of the State of Delaware, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties
require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect. Borrower’s present name, former names (if any), locations, place of formation, tax identification number,
organizational identification number and other information are correctly set forth in Exhibit C, as may be updated by Borrower in a written notice (including any Compliance Certificate) provided to Lender after the Closing Date. 

5.2. Collateral. Borrower owns all right, title and interest in and to the Collateral and the Intellectual Property, free of all
Liens whatsoever, except for Permitted Liens. Borrower has the full power and authority to grant and convey to Lender a Lien in the Collateral as security for the Secured Obligations, free of all other Liens other than Permitted Liens. 

5.3. Consents. Borrower’s execution, delivery and performance of the Notes, this Agreement and all other Loan Documents,
(i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement and the
other Loan Documents, (iii) do not violate any provisions of Borrower’s Certificate of Incorporation, bylaws, or any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as
described on Schedule 5.3, do not violate any contract or agreement or require the consent or approval of any other Person. The individual or individuals executing the Loan Documents are duly authorized to do so. 

5.4. Actions Before Governmental Authorities. Except as described on Schedule 5.4, there are no actions, suits or
proceedings at law or in equity or by or before any governmental authority now pending or, to the knowledge of Borrower, threatened against or affecting Borrower or any business, property or rights of Borrower (i) which seek to prevent, enjoin,
hinder or delay the transactions contemplated by the Loan Documents or (ii) as to which there is a reasonable possibility of an adverse determination and which, if adversely determined, would reasonably be expected to, individually or in the
aggregate, result in a Material Adverse Effect. 
 5.5. Laws. Borrower is not in violation of any law, rule or
regulation, or in default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect. Borrower is not in default in any manner
under any provision of any indenture or other agreement, contract or instrument evidencing indebtedness, or any other material agreement, contract or instrument to which it is a party or by which it or any of its properties or assets are or may be
bound and for which such default would reasonably be expected to result in a Material Adverse Effect. 

  
 9. 

 5.6. Information Correct. No information, report, Advance Request, financial
statement, exhibit or schedule furnished, by or on behalf of Borrower to Lender in connection with any Loan Document or included therein or delivered pursuant thereto, contained, contains or will contain any material misstatement of fact or, when
taken together with all other such information or documents, omitted, omits or will omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not
misleading at the time such statement was made or deemed made. Additionally, any and all financial or business projections provided by Borrower to Lender shall be (i) provided in good faith and based on the most current data and information
available to Borrower, and (ii) the most current of such projections provided to Borrower’s Board of Directors. 

5.7. Tax Matters. Except as described on Schedule 5.7, (a) Borrower has filed all federal, state and local tax returns
that it is required to file, (b) Borrower has duly paid or fully reserved for all taxes or installments thereof (including any interest or penalties) as and when due, which have or may become due pursuant to such returns, and (c) Borrower
has paid or fully reserved for any tax assessment received by Borrower for the three (3) years preceding the Closing Date, if any (including any taxes being contested in good faith and by appropriate proceedings). 

5.8. Intellectual Property Claims. Borrower is the sole owner of, or otherwise has the right to use, the Intellectual Property.
Except as described on Schedule 5.8, to Borrower’s knowledge, each of the material Copyrights, Trademarks and Patents is valid and enforceable, and no part of the Intellectual Property that is owned by Borrower has been judged invalid or
unenforceable, in whole or in part, and no claim has been made to Borrower in writing that any part of the Intellectual Property violates the rights of any third party except to the extent such claim would not reasonably be expected to cause a
Material Adverse Effect. Exhibit D is a true, correct and complete list of each of Borrower’s Patents, registered Trademarks, registered Copyrights, and material agreements under which Borrower licenses Intellectual Property from
third parties (other than shrink-wrap software licenses and other licenses which if terminated could not reasonably be expected to result in a Material Adverse Effect), together with application or registration numbers, as applicable, owned by
Borrower or any Subsidiary. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing contracts, licenses or agreements and, to Borrower’s knowledge, no third party to any
such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder. 

5.9. Intellectual Property. Except as described on Schedule 5.9, Borrower’s Intellectual Property constitutes all
rights used in or necessary in the operation or conduct of Borrower’s business as currently conducted and currently proposed to be conducted by Borrower. 
 5.10. Borrower Products. Except as described on Schedule 5.10, no Intellectual Property owned by Borrower or Borrower Product is subject to any pending or, to the knowledge of Borrower,
threatened in writing litigation, proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that
restricts in any material respect Borrower’s use, transfer or licensing thereof or that could reasonably be expected to adversely affect the validity, use or enforceability thereof. There is no outstanding decree, order, judgment, agreement,
stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any future Intellectual Property related to the operation or conduct of
the business of Borrower or Borrower Products. There is no outstanding or, to the knowledge of Borrower, threatened in writing, dispute or disagreement of which Borrower is aware with respect to any contract, license or agreement between Borrower
and any third party related to any material component or portion of the Intellectual Property. 
 5.11. Financial
Accounts. Schedule 5.11, as may be updated by Borrower in a written notice provided to Lender after the Closing Date, is a true, correct and complete list of (a) all banks and other

  
 10.

 
financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment
Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor.

 5.12. Employee Loans. Borrower has no outstanding loans to any employee, officer or director of Borrower nor has
Borrower guaranteed the payment of any loan made to an employee, officer or director of Borrower by a third party. 
 5.13.
Material Adverse Effect. Since the delivery of the most recent financial statements of Borrower delivered in accordance with Sections 7.1(a)-(c), no event that has had or would reasonably be expected to have a Material Adverse Effect has
occurred and is continuing, and Borrower is not aware of any event likely to occur that would reasonably be expected to result in a Material Adverse Effect. 
 5.14. Capitalization. Borrower’s capitalization is set forth on Schedule 5.14 annexed hereto. Borrower does not own any stock, partnership interest or other equity securities of any
Person, except for Permitted Investments. Attached as Schedule 1 hereto, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct and complete list of each Subsidiary, and all information set forth
on Schedule 1 and Schedule 5.14 is true, correct and complete. 
 SECTION 6. INSURANCE; INDEMNIFICATION 

6.1. Coverage. So long as there are any Secured Obligations outstanding, Borrower shall cause to be carried and maintained
commercial general liability insurance, on an occurrence form, against risks customarily insured against in Borrower’s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal injury,
advertising injury, and contractual liability per the terms of the indemnification agreement found in Section 6.3. Borrower must maintain a minimum of Two Million Dollars ($2,000,000.00) of commercial general liability insurance as primary
and/or excess insurance for each occurrence. So long as there are any Secured Obligations outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage
howsoever caused, in an amount not less than the full replacement cost of the Collateral. Borrower shall also carry and maintain a fidelity insurance policy in an amount not less than $150,000, together with directors’ and officers’
insurance on terms customary for companies in Borrower’s line of business and stage of development. 
 6.2.
Certificates. Borrower shall deliver to Lender certificates of insurance within thirty (30) days after the Closing Date that evidence Borrower’s compliance with its insurance obligations in Section 6.1 and the obligations
contained in this Section 6.2. Borrower’s insurance certificate shall state Lender is an additional insured for commercial general liability, an additional insured and a loss payee for all risk property damage insurance, subject to the
insurer’s approval, a loss payee for fidelity insurance, and a loss payee for property insurance and additional insured for liability insurance for any future insurance that Borrower may acquire from such insurer. Attached to the certificates
of insurance will be additional insured endorsements for liability and lender’s loss payable endorsements for all risk property damage insurance. Unless an Event of Default shall have occurred and be continuing, all insurance proceeds shall be
paid or turned over to Borrower. All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Lender of cancellation. Any failure of Lender to scrutinize such insurance certificates for compliance is
not a waiver of any of Lender’s rights, all of which are reserved. 
 6.3. Indemnity. Borrower shall and does hereby
indemnify and hold Lender, its officers, directors, employees, agents, in-house attorneys, representatives and shareholders harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs,
expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable attorneys’ fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal),

  
 11.

 
that may be instituted or asserted against or incurred by Lender or any such Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan
Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or
utilization of the Collateral, excluding in all cases claims to the extent resulting from Lender’s gross negligence willful misconduct or breach of its obligations under the Loan Documents. Borrower agrees to pay, and to save Lender harmless
from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar taxes (excluding taxes imposed on or measured by the net income of Lender) that may be payable or determined to be
payable with respect to any of the Collateral or this Agreement, except to the extent resulting from Lender’s gross negligence or willful misconduct. 
 SECTION 7. COVENANTS OF BORROWER 
 Borrower agrees as follows: 

7.1. Financial Reports. Borrower shall furnish to Lender the Compliance Certificate in the form of Exhibit F monthly within
30 days after the end of each month and the financial statements listed hereinafter, each prepared in accordance with GAAP (other than the financial statements delivered pursuant to Section 7.1(a)), consistently applied (the “Financial
Statements”): 
 (a) as soon as practicable (and in any event within thirty (30) days) after the end of
each month, unaudited interim financial statements as of the end of such month (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows accompanied by a report
detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be expected to have a Material Adverse Effect, all certified by Borrower’s Chief
Executive Officer or Chief Accounting Officer; 
 (b) as soon as practicable (and in any event within forty five
(45) days) after the end of each calendar quarter, unaudited interim and year to date financial statements as of the end of such calendar quarter (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and
related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be expected to have
a Material Adverse Effect, all certified by Borrower’s Chief Executive Officer or Chief Accounting Officer; 

(c) as soon as practicable (and in any event within 90 days after the end of each fiscal year), unqualified audited
financial statements as of the end of such year (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding
figures for the preceding fiscal year, all certified (other than the consolidating financial statements) by Ernst & Young LLP or another firm of independent certified public accountants selected by Borrower and reasonably acceptable to
Lender, accompanied by any management report from such accountants; 
 (d) promptly after the sending or filing
thereof, as the case may be, copies of any proxy statements, financial statements, materials or reports that Borrower has made available to its stockholders and copies of any regular, periodic and special reports or registration statements that
Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange (including on Forms 10Q and 10K); and 

  
 12.

 (e) financial and business projections promptly following their approval by
Borrower’s Board of Directors, as well as budgets, operating plans and other information reasonably requested by Lender. 
 The executed
Compliance Certificate may be sent via facsimile to Lender at (650) 473-9194 or via e-mail to financialstatements@herculestech.com and bjadot@herculestech.com. All Financial Statements required to be delivered pursuant to clauses (a),
(b) and (c) shall be sent via e-mail (which e-mail may contain a link to such Financial Statements) to financial statements@herculestech.com and bjadot@herculestech.com provided, that if e-mail is not available or sending such
Financial Statements via e-mail is not possible, they shall be sent via facsimile to Lender at: (650) 473-9194, attention Chief Credit Officer, reference AEGERION PHARMACEUTICALS, INC. 

7.2. Management Rights. Borrower shall permit any representative that Lender authorizes, including its attorneys and accountants,
to inspect the Collateral, examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable prior notice during normal business hours. In addition, any such representative shall have the
right to meet with management and officers of Borrower to discuss such books of account and records. In addition, Lender shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower
concerning significant business issues affecting Borrower. Such inspections or consultations shall not unreasonably interfere with Borrower’s business operations. The parties intend that the rights granted Lender shall constitute
“management rights” within the meaning of 29 C.F.R Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Lender with respect to any business issues shall not be deemed to give Lender, nor be deemed an
exercise by Lender of, control over Borrower’s management or policies. 
 7.3. Further Assurances. Borrower shall
from time to time execute, deliver and file, alone or with Lender, any financing statements, security agreements, collateral assignments, notices, control agreements, or other documents reasonably requested by Lender to perfect or give the highest
priority to Lender’s Lien on the Collateral. Borrower shall from time to time provide any instruments or documents as may be reasonably requested by Lender, and take all further action that may be necessary or desirable, or that Lender may
reasonably request, to perfect and protect the Liens granted hereby and thereby. In addition, and for such purposes only, Borrower hereby authorizes Lender to execute and deliver on behalf of Borrower and to file such financing statements,
collateral assignments, notices, control agreements, security agreements and other documents without the signature of Borrower either in Lender’s name or in the name of Lender as agent and attorney-in-fact for Borrower. Borrower shall protect
and defend Borrower’s title to the Collateral and Lender’s Lien thereon against all Persons claiming any interest adverse to Borrower or Lender. 
 7.4. Compromise of Agreements. Borrower shall not (a) grant any material extension of the time of payment of any of the Receivables or General Intangibles, (b) to any material extent,
compromise, compound or settle the same for less than the full amount thereof, (c) release, wholly or partly, any Person liable for the payment thereof in excess of $250,000 in the aggregate, or (d) allow any credit or discount whatsoever
thereon other than trade discounts granted by Borrower in the ordinary course of business of Borrower. Borrower shall not agree with any Person other than Lender not to encumber its property. 

7.5. Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or
permit any Subsidiary so to do, other than Permitted Indebtedness. 
 7.6. Collateral. Borrower shall at all times keep
the Collateral, the Intellectual Property and all other property and assets used in Borrower’s business or in which Borrower now or hereafter holds any interest free and clear from any legal process or Liens whatsoever (except for Permitted
Liens), and shall give Lender prompt written notice of any legal process affecting the Collateral, the Intellectual Property, such other property and assets, or any Liens thereon. Borrower shall cause its Subsidiaries to protect and defend such
Subsidiary’s title to its assets from and against all Persons claiming any interest adverse to such 

  
 13.

 
Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s property and assets free and clear from any legal process or Liens whatsoever (except for
Permitted Liens), and shall give Lender prompt written notice of any legal process affecting such Subsidiary’s assets. 

7.7. Investments. Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit
any of its Subsidiaries so to do, other than Permitted Investments. 
 7.8. Distributions. Borrower shall not, and shall
not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest other than pursuant to (i) employee, director or consultant repurchase plans stock option plans or agreements, restricted stock agreements or
other similar agreements, provided, however, in each case the repurchase or redemption price does not exceed the original consideration paid for such stock or equity interest or (ii) public market repurchase programs with respect to its
publicly-traded stock, provided, however, in each case the aggregate repurchase or redemption price does not exceed $1,000,000 in any fiscal year, or (b) declare or pay any cash dividend or make a cash distribution on any class of stock, except
that a Subsidiary may pay dividends or make distributions to Borrower, or (c) lend money to any employee, officer or director or guarantee the payment of any such loan granted by a third party in excess of $250,000 in the aggregate or
(d) waive, release or forgive any indebtedness owed by any employee, officer or director in excess of $250,000 in the aggregate. 
 7.9. Transfers. Except for Permitted Transfers, Borrower shall not voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal
interest in any material portion of its assets. 
 7.10. Taxes. Borrower and its Subsidiaries shall pay when due all
taxes, fees or other charges of any nature whatsoever (together with any related interest or penalties) now or hereafter imposed or assessed against Borrower, Lender or the Collateral or upon Borrower’s ownership, possession, use, operation or
disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom. Borrower shall file on or before the due date therefor all personal property tax returns in respect of the Collateral. Notwithstanding the foregoing, Borrower
may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate reserves therefor in accordance with GAAP. 
 7.11. Corporate Changes. Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without twenty (20) days’ prior written notice to
Lender. Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal place of business unless: (i) it has provided prior written notice to Lender; and (ii) such relocation shall be within the continental
United States. Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than (x) sales of Inventory in the ordinary course of business, (y) relocations of mobile equipment, or other equipment having an aggregate
value of up to $250,000 in any fiscal year, and (z) relocations of Collateral from a location described on Exhibit C to another location described on Exhibit C) unless (i) it has provided prompt written notice to Lender and (ii) such
relocation is within the continental United States. 
 7.12. Payments. Lender will initiate debit entries to
Borrower’s account as authorized in the ACH Debit Authorization in substantially the form attached as Exhibit H. 
 7.13.
Deposit Accounts. Neither Borrower nor any domestic U.S. Subsidiary shall maintain any Deposit Accounts (other than payroll, trust or escrow accounts), or accounts holding Investment Property, except with respect to (i) which Lender has
a perfected security interest in each such account or (ii) any foreign Deposit Accounts or foreign accounts holding Investment Property for which Lender shall reasonably determine that the costs of obtaining a security interest are excessive in
relation to the benefits provided to Lender of the security interest afforded thereby; provided, that Lender may require additional covenants, restrictions or Collateral from Borrower in substitution of such foreign accounts. Nothwithstanding
anything herein to the contrary, Borrower shall have thirty (30) days after the Closing Date to deliver an Account Control Agreement for the Barclays Wealth account disclosed on Schedule 5.11. 

  
 14.

 7.14. SBA. Lender has received a license from the U.S. Small Business Administration
(“SBA”) to extend loans as a small business investment company (“SBIC”) pursuant to the Small Business Investment Act of 1958, as amended, and the associated regulations (collectively, the “SBIC Act”). Portions of the
loan to Borrower will be made under the SBA license and the SBIC Act. Addendum 1 to this Agreement outlines various responsibilities of Lender and Borrower associated with an SBA loan, and such Addendum 1 is hereby incorporated in this Agreement.

 7.15. Subsidiaries. Borrower shall notify Lender of each Subsidiary formed subsequent to the Closing Date and, within
15 days of formation, shall cause any such Subsidiary organized under the laws of any State within the United States to execute and deliver to Lender a Joinder Agreement. 
 SECTION 8. [Reserved] 
 SECTION 9. EVENTS OF DEFAULT 

The occurrence of any one or more of the following events (herein called “Events of Default”) shall constitute a breach and
default under this Loan Agreement, the Notes, and the other Loan Documents: 
 9.1. Payments. Borrower fails to pay any
amount due under this Agreement, the Notes or any of the other Loan Documents on the due date thereof (the “Payment Date”); or 
 9.2. Covenants. Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, the Notes, or any of the other Loan Documents, and (a) with respect
to a default under any covenant under this Agreement (other than under Sections 6.1, 7.5, 7.6, 7.7, 7.8, 7.9 or 7.14) such default continues for more than ten (10) days after the earlier of the date on which (i) Lender has given notice of
such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 6.1, 7.5, 7.6, 7.7, 7.8, 7.9, or 7.14, the occurrence of such default; or 

9.3. Material Adverse Effect. A circumstance has occurred since the delivery of the most recent financial statements of Borrower
delivered in accordance with Sections 7.1(a)-(c) that would reasonably be expected to have a Material Adverse Effect; or 

9.4. Other Loan Documents. The occurrence of any default under any Loan Document, or any agreement between Borrower and Lender and
such default continues for more than ten (10) business days after the earlier of (a) Lender has given notice of such default to Borrower, or (b) Borrower has actual knowledge of such default; or 

9.5. Representations. Any representation or warranty made by Borrower in any Loan Document shall have been false or misleading in
any material respect when made or deemed made; or 
 9.6. Insolvency. Borrower (a) shall make an assignment for the
benefit of creditors; or (b) shall admit in writing its inability to pay its debts as they become due, or its inability to pay or perform under the Loan Documents; or (c) shall file a voluntary petition in bankruptcy; or (d) shall
file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances;
or (e) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the assets or property of Borrower; or (f) shall cease
operations of its business as its business has normally been conducted, or terminate substantially all of its employees, or shall be unable to pay its debts as they become due; or (g) Borrower or its directors shall take any action initiating
any of the foregoing actions described in clauses (a) through (f); or either (a) sixty (60) days shall have expired after the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition,
readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such 

  
 15.

 
action being dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (b) a stay of any such order or proceedings shall
thereafter be set aside and the action setting it aside shall not be timely appealed; or (c) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or
(d) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or thirty (30) days shall have expired after the appointment, without the consent or acquiescence of
Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such appointment being vacated; or 
 9.7. Attachments; Judgments. Any portion of Borrower’s assets is attached or seized, or a levy is filed against any such assets, or a judgment or judgments is/are entered for the payment of
money, individually or in the aggregate, of at least $500,000, or Borrower is enjoined or in any way prevented by court order from conducting any part of its business; or  

9.8. Other Indebtedness. The occurrence of any default under any agreement or obligation of Borrower involving any Indebtedness in
excess of $500,000 or that, when aggregated with any other such defaults would reasonably be expected to have a Material Adverse Effect. 

SECTION 10. REMEDIES 
 10.1. Upon and during the continuance of any one or more Events of Default, in accordance with applicable law (i) Lender may, at its option, accelerate and demand payment of all or any part of the
Secured Obligations together with a Prepayment Fee and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in Section 9.6, the Notes and all of the Secured
Obligations shall automatically be accelerated and made due and payable, in each case without any further notice or act), and (ii) Lender may notify any of Borrower’s account debtors to make payment directly to Lender, compromise the
amount of any such account on Borrower’s behalf and endorse Lender’s name without recourse on any such payment for deposit directly to Lender’s account. Upon and during the continuance of an Event of Default, the unpaid principal of
and accrued interest on the Notes and Advances and all outstanding Secured Obligations, including all professional fees and expenses, shall thereafter bear interest at the Default Rate. Upon and during the continuance of an Event of Default, Lender
may exercise in accordance with applicable law all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease,
liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral. All Lender’s rights and remedies shall be cumulative and not exclusive.

 10.2. Upon the occurrence and during the continuance of any Event of Default, Lender may, at any time or from time to time,
and in accordance with applicable law, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in
such order as Lender may elect. Any such sale may be made either at public or private sale at its place of business or elsewhere. Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’ prior written
notice to Borrower. Lender may require Borrower to assemble the Collateral and make it available to Lender at a place designated by Lender that is reasonably convenient to Lender and Borrower. The proceeds of any sale, disposition or other
realization upon all or any part of the Collateral shall be applied by Lender in the following order of priorities: 

First, to Lender in an amount sufficient to pay in full Lender’s costs and professionals’ and advisors’ fees and
expenses as described in Section 11.11; 
 Second, to Lender in an amount equal to the then unpaid amount of the
Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Lender may choose in its sole discretion; and 

  
 16.

 Finally, after the full, final, and indefeasible payment in Cash of all of the
Secured Obligations, to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct. 
 Lender shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC. 

10.3. Lender shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower
expressly waives all rights, if any, to require Lender to marshal any Collateral. 
 10.4. The rights, powers and remedies of
Lender hereunder shall be in addition to all rights, powers and remedies given by statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or
election of remedies with respect to any other rights, powers and remedies of Lender. 
 SECTION 11. MISCELLANEOUS 

11.1. Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the
remainder of such provision or the remaining provisions of this Agreement. 
 11.2. Notice. Except as otherwise provided
herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with respect to
the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the first business day after transmission by facsimile or hand delivery or deposit with an
overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows:

 (a) If to Lender: 
 HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 
 Legal Department 

Attention: Chief Legal Officer, Bryan Jadot and Parag Shah 
 400 Hamilton Ave. 
 Palo Alto, CA 94025 

Facsimile: 650-473-9194 
 Telephone: 617-261-6552 
 (b) If to Borrower: 

AEGERION PHARMACEUTICALS, INC. 
 Attention: Will Lewis, Chief Accounting Officer 
 101 Main Street, Suite 1850

 Cambridge, MA 02142 
 Facsimile: 908-541-1155 
 Telephone: 617-500-7867 

or to such other address as each party may designate for itself by like notice. 
 11.3. Entire Agreement; Amendments. This Agreement, the Notes, and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject

  
 17.

 
matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with
respect to the subject matter hereof or thereof (including Lender’s revised proposal letter dated February 7, 2011). None of the terms of this Agreement, the Notes or any of the other Loan Documents may be amended except by an instrument
executed by each of the parties hereto. 
 11.4. No Strict Construction. The parties hereto have participated jointly in
the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
 11.5. No Waiver.
The powers conferred upon Lender by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Lender to exercise any such powers. No omission or
delay by Lender at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which
Lender is entitled, nor shall it in any way affect the right of Lender to enforce such provisions thereafter. 
 11.6.
Survival. All agreements, representations and warranties contained in this Agreement, the Notes and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Lender and shall survive the
execution and delivery of this Agreement. 
 11.7. Successors and Assigns. The provisions of this Agreement and the other
Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement, the Notes or any of the other Loan Documents without Lender’s express
prior written consent, such consent not to be unreasonably withheld, and any such attempted assignment shall be void and of no effect. Lender may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior
notice to Borrower, and all of such rights shall inure to the benefit of Lender’s successors and assigns. 
 11.8.
Governing Law. This Agreement, the Notes and the other Loan Documents have been negotiated and delivered to Lender in the State of California, and shall have been accepted by Lender in the State of California. Payment to Lender by Borrower of
the Secured Obligations is due in the State of California. This Agreement, the Notes and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws
principles that would cause the application of laws of any other jurisdiction. 
 11.9. Consent to Jurisdiction and
Venue. All judicial proceedings (to the extent that the reference requirement of Section 11.10 is not applicable) arising in or under or related to this Agreement, the Notes or any of the other Loan Documents may be brought in any state or
federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in Santa Clara County,
State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and
(d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement, the Notes or the other Loan Documents. Service of process on any party hereto in any action arising out of or relating to this Agreement
shall be effective if given in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2. Nothing herein shall affect the right to serve process in any
other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 

  
 18.

 11.10. Mutual Waiver of Jury Trial / Judicial Reference. 

(a) Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an
experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER AND LENDER
SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY BORROWER AGAINST LENDER OR ITS ASSIGNEE OR BY
LENDER OR ITS ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than Borrower and Lender; Claims that arise out of or are in any way connected to the relationship between Borrower and
Lender; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document. 

(b) If the waiver of jury trial set forth in Section 11.10(a) is ineffective or unenforceable, the parties agree that all Claims
shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of the
Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding. 

(c) In the event Claims are to be resolved by judicial reference, either party may seek from a court of competent jurisdiction identified
in Section 11.9, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial
reference. 
 11.11. Professional Fees. Borrower promises to pay Lender’s reasonable, documented out-of-pocket fees
and expenses necessary to finalize the loan documentation, including but not limited to reasonable, documented attorneys fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable
invoiced attorneys’ and other professionals’ fees and expenses incurred by Lender after the Closing Date in connection with or related to: (a) the collection or enforcement of the Loan; (c) the amendment or modification of the
Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral;
(f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization,
assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Lender in any adversary proceeding or contested matter commenced or continued by or on
behalf of Borrower’s estate, and any appeal or review thereof. 
 11.12. Confidentiality. Lender acknowledges that
financial statements provided to Lender by Borrower and certain items of Collateral and other information provided to Lender by Borrower (if and to the extent such other information is marked as confidential by Borrower at the time of disclosure)
are confidential and proprietary information of Borrower (the “Confidential Information”). Accordingly, Lender agrees that any Confidential Information it may obtain in the course of acquiring, administering, or perfecting Lender’s
security interest in the Collateral shall not be disclosed to any other person or entity or used in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Lender may disclose any such information:
(a) to its own directors, officers, employees, accountants, counsel and other professional advisors and to its affiliates if Lender in its sole discretion determines that any such party should have access to such information in connection with
such party’s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or
(ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential 

  
 19.

 
Information; (b) if such information is generally available to the public; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority
having or claiming to have jurisdiction over Lender; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Lender’s counsel; (e) to
comply with any legal requirement or law applicable to Lender; (f) to the extent reasonably necessary in connection with the exercise of any right or remedy under any Loan Document, including Lender’s sale, lease, or other disposition of
Collateral after the occurrence and during the continuance of an Event of Default; (g) to any participant or assignee of Lender or any prospective participant or assignee; provided, that such participant or assignee or prospective
participant or assignee agrees in writing to be bound by this Section prior to disclosure; or (h) otherwise with the prior consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the
obligations of Borrower or any of its affiliates or any guarantor under this Agreement or the other Loan Documents. 
 11.13.
Assignment of Rights. Borrower acknowledges and understands that Lender may sell and assign all or part of its interest hereunder and under the Note(s) and Loan Documents to any person or entity (an “Assignee”). After such
assignment the term “Lender” as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Lender hereunder with respect to the interest so assigned; but with
respect to any such interest not so transferred, Lender shall retain all rights, powers and remedies hereby given. No such assignment by Lender shall relieve Borrower of any of its obligations hereunder. Lender agrees that in the event of any
transfer by it of the Note(s), it will endorse thereon a notation as to the portion of the principal of the Note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon.

 11.14. Revival of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and
continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any
significant part of Borrower’s assets, or if any payment or transfer of Collateral is recovered from Lender. The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or
reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or
returned by, or is recovered from, Lender or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment, performance, or transfer of Collateral
had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or
documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Lender in Cash. 
 11.15. Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate
counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 
 11.16. No Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any
kind in any person other than Lender and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal and solely between Lender and Borrower. 

11.17. Specific Performance. The parties hereto hereby declare that it is impossible to measure in money the damages which will
accrue to Lender by reason of Borrower’s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically 

  
 20.

 
enforceable by Lender. If Lender institutes any action or proceeding to specifically enforce the provisions hereof, any Person against whom such action or proceeding is brought hereby waives the
claim or defense therein that Lender has an adequate remedy at law, and such Person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 

11.18. Publicity. Lender may use Borrower’s name and logo, and include a brief description of the relationship between
Borrower and Lender, in Lender’s marketing materials with prior notice thereof to Borrower. 
 SECTION 12. COLLATERAL AGENT

 12.1. Appointment of Agent. Hercules Technology II, L.P. is hereby appointed by each Lender as Collateral Agent for
the benefit of each Lender under this Agreement and under the other Loan Documents and each Lender hereby authorizes Hercules Technology II, L.P. to act as Collateral Agent in accordance with the terms hereof and the other Loan Documents. Collateral
Agent hereby agrees to act in its capacity as such upon the express conditions contained herein and the other Loan Documents, as applicable. The provisions of this Section 12 are solely for the benefit of Collateral Agent and each Lender and
Borrower shall have any rights as a third party beneficiary of any of the provisions thereof. 
 12.2. Powers and Duties.
Each Lender irrevocably authorizes Collateral Agent to take such action on such Lender’s behalf and to exercise such powers, rights and remedies hereunder and under the other Loan Documents as are specifically delegated or granted to
Collateral Agent by the terms hereof and thereof, together with such powers, rights and remedies as are reasonably incidental thereto. Collateral Agent may exercise such powers, rights and remedies and perform such duties by or through its agents or
employees. Collateral Agent may accept payments of principal, interest, fees and expenses due under the Loan Documents from and deposits from Borrower on the account or benefit for any Lender. 

  
 21.

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and
Security Agreement as of the day and year first above written. 
  

					
	 BORROWER:
	 	AEGERION PHARMACEUTICALS, INC.
			
		 	Signature:	 	  

					
			
		 	Print Name:	 	  

					
			
		 	Title:	 	  

 Accepted in Palo Alto, California: 
 LENDER: 

 

			
	 HERCULES TECHNOLOGY II, L.P.,
 a Delaware limited partnership

		
	By:	 	Hercules Technology SBIC Management, LLC, its General Partner
		
	By:	 	Hercules Technology Growth Capital, Inc., its Manager
		
	By:	 	  

	Name:	 	  

	Its:	 	  

	
	 HERCULES TECHNOLOGY III, L.P.,
 a Delaware limited partnership

		
	By:	 	Hercules Technology SBIC Management, LLC, its General Partner
		
	By:	 	Hercules Technology Growth Capital, Inc., its Manager
		
	By:	 	  

	Name:	 	  

	Its:	 	  

  
 22.

 Table of Exhibits and Schedules 

 

			
		
	Exhibit A:	  	Advance Request
		  	Attachment to Advance Request
		
	Exhibit B:	  	Promissory Note
		
	Exhibit C:	  	Name, Locations, and Other Information for Borrower
		
	Exhibit D:	  	Borrower’s Patents, Trademarks, Copyrights and Licenses
		
	Exhibit E:	  	Borrower’s Deposit Accounts and Investment Accounts
		
	Exhibit F:	  	Compliance Certificate
		
	Exhibit G:	  	Joinder Agreement
		
	Exhibit H:	  	ACH Authorization
		
	Schedule 1	  	Subsidiaries
	Schedule 1A	  	Existing Permitted Indebtedness
	Schedule 1B	  	Existing Permitted Investments
	Schedule 1C	  	Existing Permitted Liens
	Schedule 5.3	  	Consents, Etc.
	Schedule 5.4	  	Actions Before Governmental Authorities
	Schedule 5.7	  	Tax Matters
	Schedule 5.8	  	Intellectual Property Claims
	Schedule 5.9	  	Intellectual Property
	Schedule 5.10	  	Borrower Products
	Schedule 5.11	  	Financial Accounts
	Schedule 5.14	  	Capitalization

  
 1. 

 ADDENDUM 1 to LOAN AND SECURITY AGREEMENT 

1. Borrower’s Business. For purposes of this Addendum 1, Borrower shall be deemed to include its “affiliates” as defined in Title 13
Code of Federal Regulations Section 121.103. Borrower represents and warrants to Lender (as of the Closing Date and for a period of one year thereafter) and covenants to Lender as follows: 

2. Size Status. Size Status. Borrower does not have in excess of 500 employees as of the Closing Date; 

3. No Relender. Borrower’s primary business activity does not involve, directly or indirectly, providing funds to others, purchasing debt
obligations, factoring, or long-term leasing of equipment with no provision for maintenance or repair; 
 4. No Passive Business. Borrower
is engaged in a regular and continuous business operation (excluding the mere receipt of payments such as dividends, rents, lease payments, or royalties). Borrower’s employees are carrying on the majority of day to day operations. Borrower
will not pass through substantially all of the proceeds of the Loan to another entity; 
 5. No Real Estate Business. Borrower is not classified
under Major Group 65 (Real Estate) or Industry No. 1531 (Operative Builders) of the SIC Manual. The proceeds of the Loan will not be used to acquire or refinance real property unless Borrower (x) is acquiring an existing property and
will use at least 51 percent of the usable square footage for its business purposes; (y) is building or renovating a building and will use at least 67 percent of the usable square footage for its business purposes; or (z) occupies the
subject property and uses at least 67 percent of the usable square footage for its business purposes. 
 6. No Project Finance. Borrower’s
assets are not intended to be reduced or consumed, generally without replacement, as the life of its business progresses, and the nature of Borrower’s business does not require that a stream of cash payments be made to the business’s
financing sources, on a basis associated with the continuing sale of assets (e.g., real estate development projects and oil and gas wells). The primary purpose of the Loan is not to fund production of a single item or defined limited number of
items, generally over a defined production period, where such production will constitute the majority of the activities of Borrower (e.g., motion pictures and electric generating plants). 
 7. No Farm Land Purchases. Borrower will not use the proceeds of the Loan to acquire farm land which is or is intended to be used for agricultural or forestry purposes, such as the production of food,
fiber, or wood, or is so taxed or zoned. 
 8. No Foreign Investment. The proceeds of the Loan will not be used substantially for a foreign
operation. At the time of the Loan, Borrower will not have more than 49 percent of its employees or tangible assets located outside the United States. The representation in this subsection is made only as of the date hereof and shall not
continue for one year as contemplated in the first sentence of this Section. 
 9. Small Business Administration Documentation. Lender
acknowledges that Borrower completed, executed and delivered to Lender SBA Forms 480, 652 and 1031 (Parts A and B) together with a business plan showing Borrower’s financial projections (including balance sheets and income and cash flows
statements) for the period described therein and a written statement (whether included in the purchase agreement or pursuant to a separate statement) from Lender regarding its intended use of proceeds from the sale of securities to Lender (the
“Use of Proceeds Statement”). Borrower represents and warrants to 

  
 2. 

 
Lender that the information regarding Borrower and its affiliates set forth in the SBA Form 480, Form 652 and Form 1031 and the Use of Proceeds Statement delivered as of the
Closing Date is accurate and complete. 
 10. Inspection. The following covenants are intended to supplement and not to restrict the
related provisions of the Loan Documents. Subject to the preceding sentence, Borrower will permit, for so long as Lender holds any debt or equity securities of Borrower, Lender or its representative, at Lender’ expense, and examiners of
the SBA to visit and inspect the properties and assets of Borrower, to examine its books of account and records, and to discuss Borrower’s affairs, finances and accounts with Borrower’s officers, senior management and accountants, all at
such reasonable times as may be requested by Lender or the SBA. 
 11. Annual Assessment. Promptly after the end of each calendar year (but
in any event prior to February 28 of each year) and at such other times as may be reasonably requested by Lender, Borrower will deliver to Lender a written assessment of the economic impact of Lender’ investment in Borrower, specifying the
full-time equivalent jobs created or retained in connection with the investment, the impact of the investment on the businesses of Borrower in terms of expanded revenue and taxes, other economic benefits resulting from the investment (such as
technology development or commercialization, minority business development, or expansion of exports) and such other information as may be required regarding Borrower in connection with the filing of Lender’s SBA Form 468. Lender will
assist Borrower with preparing such assessment. In addition to any other rights granted hereunder, Borrower will grant Lender and the SBA access to Borrower’s books and records for the purpose of verifying the use of such
proceeds. Borrower also will furnish or cause to be furnished to Lender such other information regarding the business, affairs and condition of Borrower as Lender may from time to time reasonably request. 

Use of Proceeds. Borrower will use the proceeds from the Loan only for general working capital purposes. Borrower will deliver to Lender from time
to time promptly following Lender’s request, a written report, certified as correct by Borrower’s Chief Accounting Officer, verifying the purposes and amounts for which proceeds from the Loan have been disbursed. Borrower will supply
to Lender such additional information and documents as Lender reasonably requests with respect to its use of proceeds and will permit Lender and the SBA to have access to any and all Borrower records and information and personnel as Lender deems
necessary to verify how such proceeds have been or are being used, and to assure that the proceeds have been used for the purposes specified in this Section. 
 12. Activities and Proceeds. Neither Borrower nor any of its affiliates (if any) will engage in any activities or use directly or indirectly the proceeds from the Loan for any purpose for which a small
business investment company is prohibited from providing funds by the SBIC Act, including 13 C.F.R. §107.720. Without obtaining the prior written approval of Lender, Borrower will not change within 1 year of the date hereof,
Borrower’s current business activity to a business activity which a licensee under the SBIC Act is prohibited from providing funds by the SBIC Act. 
 13. Reserved. 
 14. Cost of Money. Notwithstanding any provision to the contrary contained in the
Loan Documents, all interest and fees charged pursuant to the Loan Documents shall comply with the provisions of 13 C.F.R. § 107.855, including, without limitation, that such amounts shall not exceed the Cost of Money ceiling (as defined
hereafter). The current Cost of Money ceiling for this Loan is 14.5%. 
 15. Compliance and Resolution. Borrower agrees that a failure to
comply with Borrower’s obligations under this Addendum, or any other set of facts or circumstances where it has been asserted by any governmental regulatory agency (or Lender believes that there is a substantial risk of such assertion) that
Lender and its affiliates are not entitled to hold, or exercise any significant right with respect to, any 

  
 3. 

 
securities issued to Lender by Borrower, will constitute a breach of the obligations of Borrower under the financing agreements between Borrower and Lender. In the event of (i) a
failure to comply with Borrower’s obligations under this Addendum; or (ii) an assertion by any governmental regulatory agency (or Lender believes that there is a substantial risk of such assertion) of a failure to comply with
Borrower’s obligations under this Addendum, then (i) Lender and Borrower will meet and resolve any such issue in good faith to the satisfaction of Borrower, Lender, and any governmental regulatory agency, and (ii) upon request of
Lender, Borrower will cooperate and assist with any assignment of the financing agreements from Hercules Technology II, L.P. and/or Hercules Technology III, L.P. to Hercules Technology Growth Capital, Inc. 

  
 4. 

 EXHIBIT A 
 ADVANCE REQUEST 
  

					
	To:	  	Lender:	  	Date:                     , 20    

		  	Hercules Technology II, L.P.	  	
		  	Hercules Technology III, L.P.	  	
		  	400 Hamilton Avenue	  	
		  	Palo Alto, CA 94301	  	
		  	Facsimile: 650-473-9194	  	
		  	Attn:	  	

 AEGERION PHARMACEUTICALS, INC. (“Borrower”) hereby requests from Hercules Technology II, L.P. and
Hercules Technology III, L.P. (collectively “Lender”) an Advance in the amount of
                                        
Dollars ($                    .00) on
                    ,          (the “Advance Date”) pursuant to the Loan and Security
Agreement between Borrower and Lender (the “Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement. 

Please: 
  

													
	(a)	  	Issue a check payable to Borrower	 		 	              
	 		 	
							
		  	or	 		 		 		 		 	
						
	(b)	  	Wire Funds to Borrower’s account	 		 	              
	 		 	
						
		  	Bank:	 	  
	 		 		 	
		  	Address:	 	  
	 		 	
		  		 	  
	 		 	
		  	ABA Number:	 	  
	 		 	
		  	Account Number:	 	  
	 		 	
		  	Account Name:	 	  
	 		 		 	

 Borrower represents that the conditions precedent to the Advance set forth in the Agreement are
satisfied and shall be satisfied upon the making of such Advance, including but not limited to: (i) that since the delivery of the most recent financial statements of Borrower delivered in accordance with Sections 7.1(a)-(c), no Material
Adverse Effect has occurred and is continuing; (ii) that the representations and warranties set forth in the Agreement are and shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made
on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date; (iii) that Borrower is in compliance in all material respects with the terms and provisions set forth in each Loan Document on
its part to be observed or performed; and (iv) that as of the Advance Date, no fact or condition exists that would constitute an Event of Default under the Agreement. Borrower understands and acknowledges that Lender has the right to review the
financial information supporting this representation and, based upon such review in its reasonable discretion, Lender may decline to fund the requested Advance if such representation is not true and correct. 

Borrower hereby represents that Borrower’s corporate status and locations have not changed since the date of this Agreement or, if
the Attachment to this Advance Request is completed, are as set forth in the Attachment to this Advance Request. 

  
 5. 

 Borrower agrees to notify Lender promptly before the funding of the Loan if any of the
matters which have been represented above shall not be true and correct in all material respects on the Advance Date and if Lender has received no such notice before the Advance Date then the statements set forth above shall be deemed to have been
made and shall be deemed to be true and correct as of the Advance Date. 
 Executed as of
                    , 200    . 
  

					
		  	BORROWER: AEGERION PHARMACEUTICALS, INC.
			
		  	SIGNATURE:	  	  

		  	TITLE:	  	Chief Executive Officer or Chief Accounting Officer
		  	PRINT NAME:	  	  

  
 6. 

 ATTACHMENT TO ADVANCE REQUEST 

Dated:
                                        

 Borrower hereby represents and warrants to Lender that Borrower’s current name and organizational status is as follows: 

 

					
	Name:	    	Aegerion Pharmaceuticals, Inc.	  	
			
	Type of organization:	    	Corporation	  	
			
	State of organization:	    	Delaware	  	
			
	Organization file number:	    	  
	  	

 Borrower hereby represents and warrants to Lender that the street addresses, cities, states and postal codes of
its current locations are as follows: 
  

					
	 Chief Executive Office

and Principal Place of Business:
	    	101 Main Street, Suite 1850	  	
		    	Cambridge, MA 02142	  	
			
		    	7	  	
			
	Locations of Collateral:	    	Same as above	  	

  
 7. 

 EXHIBIT B-1 

SECURED PROMISSORY NOTE 
  

			
	[$                    ]	 	Advance Date: February     , 2011
		 	Maturity Date: September 1, 2014

 FOR VALUE RECEIVED, AEGERION PHARMACEUTICALS, INC., a Delaware corporation, for itself and each of its Subsidiaries (the “Borrower”) hereby promises to pay to the order of Hercules Technology
II, L.P., a Delaware limited partnership or the holder of this Note (the “Lender”) at 400 Hamilton Avenue, Palo Alto, CA 94301 or such other place of payment as the holder of this Secured Promissory Note (this “Promissory Note”)
may specify from time to time in writing, in lawful money of the United States of America, the principal amount of [            ] together with interest at a floating rate equal to the
greater of (i) 10.4% per annum or (ii) 10.4% plus (a) the Prime Rate as reported in The Wall Street Journal minus 4.75% per annum based upon a year consisting of 360 days, with interest computed daily based on the
actual number of days in each month. 
 This Promissory Note is the Note referred to in, and is executed and delivered in
connection with, that certain Loan and Security Agreement dated February     , 2011, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms,
the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions
thereof. All payments shall be made in accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall
constitute a default under this Promissory Note. Reference to the Loan Agreement shall not affect or impair the absolute and unconditional obligation of Borrowers to pay all principal and interest and premium, if any, under this Promissory Note upon
demand or as otherwise provided herein 
 Borrower waives presentment and demand for payment, notice of dishonor, protest and
notice of protest under the UCC or any applicable law. Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory Note has been negotiated
and delivered to Lender and is payable in the State of California. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or principles that
would cause the application of the laws of any other jurisdiction. 
  

					
	BORROWER FOR ITSELF AND	 		 	
	ON BEHALF OF ITS SUBSIDIARIES:	 	AEGERION PHARMACEUTICALS, INC.
			
		 	By:	 	  

		 	Title:	 	  

  
 8. 

 EXHIBIT B-2 

SECURED PROMISSORY NOTE 
  

			
	[$                    ]	 	Advance Date: February     , 2011
		 	Maturity Date: September 1, 2014

 FOR VALUE RECEIVED, AEGERION PHARMACEUTICALS, INC., a Delaware corporation, for itself and each of its Subsidiaries (the “Borrower”) hereby promises to pay to the order of Hercules Technology
III, L.P., a Delaware limited partnership or the holder of this Note (the “Lender”) at 400 Hamilton Avenue, Palo Alto, CA 94301 or such other place of payment as the holder of this Secured Promissory Note (this “Promissory Note”)
may specify from time to time in writing, in lawful money of the United States of America, the principal amount of [$            ] together with interest at a floating rate equal to the
greater of (i) 10.4% per annum or (ii) 10.4% plus (a) the Prime Rate as reported in The Wall Street Journal minus 4.75% per annum based upon a year consisting of 360 days, with interest computed daily based on the
actual number of days in each month. 
 This Promissory Note is the Note referred to in, and is executed and delivered in
connection with, that certain Loan and Security Agreement dated February     , 2011, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms,
the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions
thereof. All payments shall be made in accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall
constitute a default under this Promissory Note. Reference to the Loan Agreement shall not affect or impair the absolute and unconditional obligation of Borrowers to pay all principal and interest and premium, if any, under this Promissory Note upon
demand or as otherwise provided herein 
 Borrower waives presentment and demand for payment, notice of dishonor, protest and
notice of protest under the UCC or any applicable law. Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory Note has been negotiated
and delivered to Lender and is payable in the State of California. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or principles that
would cause the application of the laws of any other jurisdiction. 
  

					
	BORROWER FOR ITSELF AND	 		 	
	ON BEHALF OF ITS SUBSIDIARIES:	 	AEGERION PHARMACEUTICALS, INC.
			
		 	By:	 	  

		 	Title:	 	  

  
 9. 

 EXHIBIT C 

NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER 
 1. Borrower represents and warrants to Lender that Borrower’s current name and organizational status as of the Closing Date is as follows: 

 

							
	Name:	 	Aegerion Pharmaceuticals, Inc.	  		  	
				
	Type of organization:	 	Corporation	  		  	
				
	State of organization:	 	Delaware	  		  	
				
	Organization file number:	 	  
	  		  	

 2. Borrower represents and warrants to Lender that for five (5) years prior to the Closing
Date, Borrower did not do business under any other name or organization or form except the following: 

    Name: 
     Used during dates of: 
     Type of
Organization: 
     State of organization: 

    Organization file Number: 
     Borrower’s fiscal year ends on December 31 

    Borrower’s federal employer tax identification number is:
                     

3. Borrower represents and warrants to Lender that the street addresses, cities, states and postal codes of its current locations as of
the Closing Date are: 
  

							
	Chief Executive Office:	 	101 Main Street, Suite 1850	  		  	
		 	Cambridge, MA 02142	  		  	
				
	    Principal Place of Business:
	 	Same as above.	  		  	
				
	Locations of Collateral:	 	Same as above	  		  	

  
 10.

 EXHIBIT D 

BORROWER’S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES 

EXHIBIT E 
 RESERVED 

  
 11.

 EXHIBIT F 

COMPLIANCE CERTIFICATE 

Hercules Technology II, L.P. 
 Hercules
Technology III, L.P. 
 400 Hamilton Avenue 
 Palo Alto, CA 94301 
 Re: Reference is made to that certain Loan and Security
Agreement dated February     , 2011 and all ancillary documents entered into in connection with such Loan and Security Agreement all as may be amended from time to time, (hereinafter referred to collectively as the
“Loan Agreement”) between Hercules Technology II, L.P. and Hercules Technology III, L.P. (“Hercules”) as Lender and Aegerion Pharmaceuticals, Inc. (the “Company”) as Borrower. All capitalized terms not defined herein
shall have the same meaning as defined in the Loan Agreement. 
 Gentlemen: 

The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is authorized to provided certification
of information regarding the Company; hereby certifies that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance in all material respects for the period ending
                     of all covenants, conditions and terms and hereby reaffirms that all representations and warrants contained therein are
true and correct in all material respects on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date,
after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties. Attached are the required documents supporting the above certification. The undersigned further certifies
that these are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year end adjustments) and are consistent from one period to the next except as explained below.

  

					
	 REPORTING REQUIREMENT
	 	 REQUIRED
	 	 CHECK IF ATTACHED

	Interim Financial Statements	 	Monthly within 30 days	 	
	Interim Financial Statements	 	Quarterly within 45 days	 	
	Audited Financial Statements	 	FYE within 90 days	 	

  

			
	Very Truly Yours,
		
	By:	 	  

		
	Name:	 	  

		
	Its:	 	  

  
 12.

 EXHIBIT G 

FORM OF JOINDER AGREEMENT 
 JOINDER AGREEMENT 
 This Joinder Agreement (the “Joinder
Agreement”) is made and dated as of February     , 2011, and is entered into by and between
                                        
(“Subsidiary”), and Hercules Technology II, L.P. and Hercules Technology III, L.P. (collectively, “Lender”). 

RECITALS 

A. Subsidiary’s Affiliate, Aegerion Pharmaceuticals, Inc. (“Company”) desires to enter into that certain Loan and Security
Agreement dated February     , 2011, with Lender, as such agreement may be amended (the “Loan Agreement”), together with the other agreements executed and delivered in connection therewith; 

B. Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company’s execution of the Loan
Agreement and the other agreements executed and delivered in connection therewith; 
 AGREEMENT 

NOW THEREFORE, Subsidiary and Lender agree as follows: 
  

	1.	The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized terms not defined herein shall have the meaning provided in the
Loan Agreement. 

  

	2.	By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were Borrower (as defined in the Loan
Agreement) under the Loan Agreement, mutatis mutandis, provided however, that Lender shall have no duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other agreements executed and
delivered in connection therewith. Rather, to the extent that Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith, those duties,
responsibilities or obligations shall flow only to Company and not to Subsidiary or any other person or entity. By way of example (and not an exclusive list): (a) Agent or a Lender’s providing notice to Company in accordance with the Loan
Agreement or as otherwise agreed between Company and Lender shall be deemed provided to Subsidiary; (b) a Lender’s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (c) Subsidiary shall have no right to
request an Advance or make any other demand on Agent or a Lender. 

  

			
	SUBSIDIARY:	 	  

		
	By:	 	  

	Name:	 	  

	Title:	 	  

		
	Address:	 	
		
	Telephone:	 	  

	Facsimile:	 	  

  
 13.

 
					
	HERCULES TECHNOLOGY II, L.P.,
	a Delaware limited partnership
	By:	 	Hercules Technology SBIC Management, LLC,
		 	its General Partner
	By:	 	Hercules Technology Growth Capital, Inc.,
		 	its Manager
		 	By:	 	  

		 	Name:	 	  

		 	Its:	 	  

	
	HERCULES TECHNOLOGY III, L.P.,
	a Delaware limited partnership
	By:	 	Hercules Technology SBIC Management, LLC,
		 	its General Partner
	By:	 	Hercules Technology Growth Capital, Inc.,
		 	its Manager
		 	By:	 	  

		 	Name:	 	  

		 	Its:	 	  

  
 14.

 EXHIBIT H 
 FORM OF 
 ACH DEBIT AUTHORIZATION AGREEMENT 

Hercules Technology II, L.P. 
 Hercules
Technology III, L.P. 
 400 Hamilton Avenue, Suite 310 
 Palo Alto, CA 94301 
 Re: Loan and Security Agreement dated February
    , 2011 between AEGERION PHARMACEUTICALS, INC. (“Borrower”) and Hercules Technology II, L.P. and Hercules Technology III, L.P. (collectively, “Company”) (the “Agreement”) 

In connection with the above referenced Agreement, Borrower hereby authorizes the Company to initiate debit entries for the periodic payments due under
the Agreement to Borrower’s account indicated below. Borrower authorizes the depository institution named below to debit to such account. 
  

			
	  
	    	  

	DEPOSITORY NAME	    	BRANCH
		
	  
	    	  

	CITY	    	STATE AND ZIP CODE
		
	  
	    	  

	TRANSIT/ABA NUMBER	    	ACCOUNT NUMBER
		
	  
	    	  

 This authority will remain in full force and effect so long as any amounts are due under the Agreement. 
 AEGERION PHARMACEUTICALS, INC. 
  

			
	By:	 	  

		
	Date:	 	  

  
 15.

 LOAN AND SECURITY AGREEMENT 

 
  

SCHEDULES 
  

 
 Aegerion Pharmaceuticals, Inc.
(“Aegerion” or “Borrower”) has prepared these Schedules pursuant to the Loan and Security Agreement, dated February     , 2011, between Borrower and Hercules Technology II, L.P., a Delaware limited
partnership, and Hercules Technology III, L.P., a Delaware limited partnership (collectively, “Lender”), (the “Agreement”). Descriptive headings in the Schedules are inserted only for reference purposes and for convenience of the
reader. Capitalized terms used but not defined in these Schedules shall have the meanings assigned to them in the Agreement. 
 If the
disclosure provided by the Borrower in the Schedules is in greater detail than is required by the particular representation and warranty of Borrower in Section 5 of the Agreement, such disclosure is not an admission by Borrower that it believes
the disclosed information is material or not in the ordinary course of business. Furthermore, a threshold of materiality being provided by Borrower on a particular section of the Schedules, if any, is not intended to be an indication of the
threshold of materiality for any other section of the Schedules or for any purpose under the Agreement. Nothing in the Schedules constitutes an admission of any liability or obligation of Borrower to any third party or an admission against the
interest of Borrower. 
 This Schedules are accurate and complete as of the date of the Agreement. Disclosure in one section of the Schedules
shall constitute disclosure for all sections hereof, to the extent that the applicability of such disclosure is manifestly apparent. 

 Schedule 1 
 Subsidiaries 
 None. 

 Schedule 1A 
 Existing Permitted Indebtedness 
 None. 

  
 18 

 Schedule 1B 
 Existing Permitted Investments 
 Aegerion currently invests its cash in a money market
account with TD Bank. NA (see Schedule 5.11). 

  
 19 

 Schedule 1C 
 Existing Permitted Liens 
 None. 

  
 20 

 Schedule 5.3 
 Consents 
 None. 

  
 21 

 Schedule 5.4 
 Actions Before Governmental Authorities 
  

	1.	The Company entered into a Consulting Agreement with Dr. Jonathan Stamler of Duke University on November 19, 2007. On November 10, 2009, the Company
terminated its consulting agreement with Dr. Stamler for cause and informed Dr. Stamler that it intended to cancel his options to purchase 275,000 shares of Common Stock. In a letter dated January 25, 2010, counsel for
Dr. Stamler objected to the Company’s termination for cause and accused the Company of being in breach of the Consulting Agreement for failure to pay consulting fees. The matter was dormant for approximately one year and then, on
February 9, 2011, Dr. Stamler’s lawyers sent another letter indicating that Dr. Stamler’s position with respect to the alleged breach had not changed and that, in addition to consulting fees, he was seeking compensation for
his terminated options. Aggregate unpaid consulting fees for this agreement, if breached, would be approximately $160,000, and the value of terminated options depends on the date of exercise which would be permitted until 2017. The Company, however,
maintains that Dr. Stamler is in breach of the Consulting Agreement and the Company has informed Dr. Stamler that it reserves the right to pursue remedies against him, including by seeking recovery of previously-paid consulting fees.

  

	2.	The Company entered into a Project Agreement with NuModa Corporation (“NuModa”) effective as of February 4, 2010 for the Phase 2 trial in the severe
Refractory HeFH population. The Company subsequently terminated the Project Agreement following feedback from the FDA with respect to this patient population. Per the Project Agreement, the Company owes NuModa the reasonable value of any Services
provided and costs incurred thereunder through the date of termination and any wind-down period. 

  
 22 

 Schedule 5.7 
 Tax Matters 
 None. 

 Schedule 5.8 
 Intellectual Property Claims 
 On September 27, 2006, Aegerion entered into a
Settlement and Cross-License Agreement with The Trustees of the University of Pennsylvania and Pfizer Inc. of New York (“Pfizer”) to settle an interference declared by the U.S. Patent & Trademark Office between a U.S. patent
application owned by Pfizer and an issued U.S. patent licensed to Aegerion by UPenn. There are no payments due to or from Aegerion under the Settlement and Cross-License Agreement. The cross-licenses granted by the parties under the Settlement and
Cross-License Agreement are perpetual and irrevocable. 

 Schedule 5.9 
 Intellectual Property 
 None. 

 Schedule 5.10 
 Borrower Products 
 None. 

 Schedule 5.11 
 Financial Accounts 
  

	1.	Bank: TD Bank, NA 

Account: 2759500016 – INVESTMENT ACCOUNT (USD) 

 

	2.	Bank: TD Bank, NA 

Account: 7861047020 – PAYROLL ACCOUNT (USD) 
  

	3.	Bank: TD Bank, NA 

Account: 7861047038 – OPERATING ACCOUNT (USD) 
  

	4.	Bank: Barclays Wealth, a division of Barclays Bank PLC 

 Account: 831-03415-1-9-654 – BROKERS’ ACCOUNT 
  

	 	•	 	 Primus FINL PRODF LLC auction rate security, par value $1,500,000 

 

	 	•	 	 MBIA Insurance Corp. perpetual preferred, par value $1,500,000 

 

	 	•	 	 Federated Money Market Account for interest and dividends 

 

	5.	Bank: TD Bank, NA 

Account: 7867050507 – AEGERION PHARMACEUTICALS, INC. 

 Schedule 5.14 
 Capitalization 
 Aegerion is authorized to 125,000,000 shares of Common Stock and 5,000,000
shares of Undesignated Preferred Stock. 
  

									
	 	  	Common Stock	 	  	Series A
Preferred
Stock	 
	 Outstanding
	  	 	17,641,543	  	  	 	0	  
		  	 	 	 	  	 	 	 
			
	 Outstanding Options
	  	 	1,715,813	  	  			
	 Options Available for Grant
	  	 	2,621,127	  	  			
		  	 	 	 	  	 	 	 
			
	 TOTAL Outstanding with Options
	  	 	21,978,483	  	  	 	0Summary of Director Compensation for Fiscal 2010

 Exhibit 10.18 
 Summary of Director Compensation for Fiscal 2010 
 Each member of the Board of
Directors who is not an employee of Tredegar or any of its subsidiaries receives the following annual retainers, payable in equal quarterly installments in arrears: 
  

					
	 Non-Employee Director
	  	$	50,000	  
	 Chairman of the Board
	  	$	20,000	  
	 Audit Committee Chairperson
	  	$	14,000	  
	 Non-Chair Member of the Audit Committee
	  	$	7,500	  
	 Executive Compensation Committee Chairperson
	  	$	9,000	  
	 Non-Chair Member of the Executive Compensation Committee
	  	$	5,000	  
	 Nominating and Governance Committee Chairperson
	  	$	6,000	  
	 Non-Chair Member of the Nominating and Governance Committee
	  	$	3,000	  
	 Executive Committee Chairperson
	  	$	9,000	  
	 Non-Chair Member of the Executive Committee
	  	$	4,500	  
	 Member of the Investment Policy Committee
	  	$	625	  

 The retainer paid to non-employee
directors is paid $30,000 in cash and $20,000 in the form of a stock award. The stock award is determined based on the closing price of Tredegar common stock as reported on the New York Stock Exchange composite on the date of grant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}]]